Dendreon Corp (NASDAQ: DNDN) shares have spiraled high just before trade was halted at 12:34 pm EST. The stock made a jump on a Fox Business report of the FDA approving Dendreon’s PROVENGE as a late-stage treatment for prostate cancer.

This approval was long awaited by shareholders, traders and people suffering from advanced prostate cancer.

Read the rest of this story on Benzinga